CAS
910463-68-2
AA-Sequence
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Originator
Novo Nordisk
First marketed by
Novo Nordisk
Name of FDF
Ozemopic®, Rybelsus®
Original FDF
RTU solution for subcutaneous injection
Other FDF
Oral tablets
Mode of Action
Glucagon like peptide 1 receptor agonists
Indications
Obesity, type 2 diabetes mellitus
Patent status
Subcutaneous formulation is still patented until 2027-12-05. Oral formulation is patented until 2029-09-20